As of May 27, 2025, Visiodent SA's estimated intrinsic value ranges from $0.48 to $5.58 per share, depending on the valuation methodology applied.
| Valuation Method | Fair Value (USD) | Implied Upside/Downside |
|---|---|---|
| Discounted Cash Flow (10Y) | $5.02 | +67.5% |
| Discounted Cash Flow (5Y) | $3.10 | +3.3% |
| Dividend Discount Model (Multi-Stage) | $3.04 | +1.3% |
| Dividend Discount Model (Stable) | $5.58 | +86.1% |
| Earnings Power Value | $0.48 | -84.0% |
Is Visiodent SA (SDT.PA) undervalued or overvalued?
With the current market price at $3.00, the stock appears to be significantly undervalued.
Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate Visiodent SA's intrinsic value, including:
The cost of capital is a critical factor in valuation models, representing the required return for investors.
| WACC Component | Low | High |
|---|---|---|
| Long-term bond rate | 2.6% | 3.1% |
| Equity market risk premium | 5.2% | 6.2% |
| Adjusted beta | 0.81 | 1.01 |
| Cost of equity | 6.8% | 9.9% |
| Cost of debt | 5.0% | 5.0% |
| Tax rate | 29.8% | 31.8% |
| Debt/Equity ratio | 0.19 | 0.19 |
| After-tax WACC | 6.3% | 8.8% |
Our DCF model projects cash flows over 5-year and 10-year horizons, with the following key assumptions:
| DCF Model | Fair Value | Enterprise Value | % from Terminal Value |
|---|---|---|---|
| 5-Year Growth | $3 | $13M | 83.7% |
| 10-Year Growth | $5 | $22M | 72.3% |
| 5-Year EBITDA | $4 | $19M | 88.5% |
| 10-Year EBITDA | $5 | $22M | 73.2% |
The DDM values a company based on its expected future dividend payments. We used two approaches:
EPV assesses a company's value based on its current normalized earnings power, assuming no growth.
| EPV Component | Value |
|---|---|
| Normalized Earnings | $0M |
| Discount Rate (WACC) | 8.8% - 6.3% |
| Enterprise Value | $1M - $1M |
| Net Debt | $(1)M |
| Equity Value | $2M - $2M |
| Outstanding Shares | 4M |
| Fair Value | $0 - $1 |
| Selected Fair Value | $0.48 |
| Metric | Value |
|---|---|
| Market Capitalization | $13M |
| Enterprise Value | $13M |
| Trailing P/E | 10.96 |
| Forward P/E | 33.33 |
| Trailing EV/EBITDA | 7.20 |
| Current Dividend Yield | 333.33% |
| Dividend Growth Rate (5Y) | -100.00% |
| Debt-to-Equity Ratio | 0.19 |
To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:
| Valuation Method | Weight | Weighted Value |
|---|---|---|
| Discounted Cash Flow (10Y) | 30% | $1.51 |
| Discounted Cash Flow (5Y) | 25% | $0.77 |
| Dividend Discount Model (Multi-Stage) | 20% | $0.61 |
| Dividend Discount Model (Stable) | 15% | $0.84 |
| Earnings Power Value | 10% | $0.05 |
| Weighted Average | 100% | $3.77 |
Based on our comprehensive valuation analysis, Visiodent SA's weighted average intrinsic value is $3.77, which is approximately 25.8% above the current market price of $3.00.
Key investment considerations:
Given these factors, we believe Visiodent SA is currently significantly undervalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.